innovatis will become a fully-integrated part of Roche Applied Science, a global business area of the diagnostic division of Roche. The company will continue to develop and market products for cell analysis through Roche Applied Science’s extensive worldwide network.
The transaction is expected to be completed shortly, subject to shareholder approval and regulatory clearance.
Jurgen Schwiezer, CEO of Roche Diagnostics division, said: “This acquisition is a further step in our strategy to strengthen our position as a complete solution provider in the cell analysis research market. innovatis’s technology will complement the existing Roche cell analysis portfolio and is synergistic to the xCELLigence technology launched in 2008.”